Pharma apms learning curve awaits you pharma

As pharmaceutical manufacturers face increasing public pressure over prices and value, we believe the advantages of pharmaceutical alternative payment models (APMs) will be increasingly attractive to both pharmaceutical manufacturers and insurers. But pharmaceutical APMs are more nuanced and resource intensive than the traditional fee-for-service contracts that pharmaceutical manufacturers negotiate with payers. There are some valuable lessons for pharmaceutical manufacturers in provider APMs, but whether pharmaceutical APMs succeed or fail will depend on finding solutions to operational and logistical challenges—some of which are unique to the pharmaceutical industry.

There are a few valuable lessons for pharmaceutical manufacturers in provider alternative payment models (APMs), however, if pharmaceutical APMs fail or succeed will depend upon finding methods to operational and logistical challenges-some which can be exceptional to the pharmaceutical trade. Pharmaceutical APMs will require the selection of advice beyond the claims data that lots of provider APMs rely upon.

Our most popular topics on